 | • レポートコード：GIR201107302 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、閉経後骨粗鬆症治療薬の世界市場を調査対象にし、閉経後骨粗鬆症治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（吸収抑制薬、アナボリック薬）、用途別分析（病院、薬局、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：Eli Lilly、Noven、Novartis、Amgen、Deltanoid Pharmaceuticals、Merck、Osteologix、Amgen Astellas Biopharm、Allergan、Novo Nordisk、Pfizer、Tarsa Therapeutics、PhytoHealth、Radius Health ・メーカー別販売量、売上、市場シェア ・閉経後骨粗鬆症治療薬の地域別市場分析 ・閉経後骨粗鬆症治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・閉経後骨粗鬆症治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・閉経後骨粗鬆症治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・閉経後骨粗鬆症治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・閉経後骨粗鬆症治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・閉経後骨粗鬆症治療薬の種類別市場規模2015-2020：吸収抑制薬、アナボリック薬 ・閉経後骨粗鬆症治療薬の用途別市場規模2015-2020：病院、薬局、その他 ・閉経後骨粗鬆症治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Postmenopausal Osteoporosis Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Postmenopausal Osteoporosis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Postmenopausal Osteoporosis Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Postmenopausal Osteoporosis Drugs market has been segmented into
Antiresorptive Medications
Anabolic Medications
By Application, Postmenopausal Osteoporosis Drugs has been segmented into:
Hospital
Pharmacy
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Postmenopausal Osteoporosis Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Postmenopausal Osteoporosis Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Postmenopausal Osteoporosis Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Postmenopausal Osteoporosis Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Postmenopausal Osteoporosis Drugs Market Share Analysis
Postmenopausal Osteoporosis Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Postmenopausal Osteoporosis Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Postmenopausal Osteoporosis Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Postmenopausal Osteoporosis Drugs are:
Eli Lilly
Noven
Novartis
Amgen
Deltanoid Pharmaceuticals
Merck
Osteologix
Amgen Astellas Biopharm
Allergan
Novo Nordisk
Pfizer
Tarsa Therapeutics
PhytoHealth
Radius Health
Among other players domestic and global, Postmenopausal Osteoporosis Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Postmenopausal Osteoporosis Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Postmenopausal Osteoporosis Drugs, with price, sales, revenue and global market share of Postmenopausal Osteoporosis Drugs in 2018 and 2019.
Chapter 3, the Postmenopausal Osteoporosis Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Postmenopausal Osteoporosis Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Postmenopausal Osteoporosis Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Postmenopausal Osteoporosis Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Postmenopausal Osteoporosis Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Postmenopausal Osteoporosis Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Antiresorptive Medications
1.2.3 Anabolic Medications
1.3 Market Analysis by Application
1.3.1 Overview: Global Postmenopausal Osteoporosis Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Overview of Global Postmenopausal Osteoporosis Drugs Market
1.4.1 Global Postmenopausal Osteoporosis Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Eli Lilly SWOT Analysis
2.1.4 Eli Lilly Product and Services
2.1.5 Eli Lilly Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Noven
2.2.1 Noven Details
2.2.2 Noven Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Noven SWOT Analysis
2.2.4 Noven Product and Services
2.2.5 Noven Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis SWOT Analysis
2.3.4 Novartis Product and Services
2.3.5 Novartis Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Amgen SWOT Analysis
2.4.4 Amgen Product and Services
2.4.5 Amgen Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Deltanoid Pharmaceuticals
2.5.1 Deltanoid Pharmaceuticals Details
2.5.2 Deltanoid Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Deltanoid Pharmaceuticals SWOT Analysis
2.5.4 Deltanoid Pharmaceuticals Product and Services
2.5.5 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Merck SWOT Analysis
2.6.4 Merck Product and Services
2.6.5 Merck Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Osteologix
2.7.1 Osteologix Details
2.7.2 Osteologix Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Osteologix SWOT Analysis
2.7.4 Osteologix Product and Services
2.7.5 Osteologix Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Amgen Astellas Biopharm
2.8.1 Amgen Astellas Biopharm Details
2.8.2 Amgen Astellas Biopharm Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Amgen Astellas Biopharm SWOT Analysis
2.8.4 Amgen Astellas Biopharm Product and Services
2.8.5 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Allergan
2.9.1 Allergan Details
2.9.2 Allergan Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Allergan SWOT Analysis
2.9.4 Allergan Product and Services
2.9.5 Allergan Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Novo Nordisk
2.10.1 Novo Nordisk Details
2.10.2 Novo Nordisk Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Novo Nordisk SWOT Analysis
2.10.4 Novo Nordisk Product and Services
2.10.5 Novo Nordisk Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Pfizer
2.11.1 Pfizer Details
2.11.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Pfizer SWOT Analysis
2.11.4 Pfizer Product and Services
2.11.5 Pfizer Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Tarsa Therapeutics
2.12.1 Tarsa Therapeutics Details
2.12.2 Tarsa Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Tarsa Therapeutics SWOT Analysis
2.12.4 Tarsa Therapeutics Product and Services
2.12.5 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 PhytoHealth
2.13.1 PhytoHealth Details
2.13.2 PhytoHealth Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 PhytoHealth SWOT Analysis
2.13.4 PhytoHealth Product and Services
2.13.5 PhytoHealth Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Radius Health
2.14.1 Radius Health Details
2.14.2 Radius Health Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Radius Health SWOT Analysis
2.14.4 Radius Health Product and Services
2.14.5 Radius Health Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Postmenopausal Osteoporosis Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Postmenopausal Osteoporosis Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Postmenopausal Osteoporosis Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Postmenopausal Osteoporosis Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Postmenopausal Osteoporosis Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Postmenopausal Osteoporosis Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Postmenopausal Osteoporosis Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
4.5 South America Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Postmenopausal Osteoporosis Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Postmenopausal Osteoporosis Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Postmenopausal Osteoporosis Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Postmenopausal Osteoporosis Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Postmenopausal Osteoporosis Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Postmenopausal Osteoporosis Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
6.3 UK Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
6.4 France Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Postmenopausal Osteoporosis Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Postmenopausal Osteoporosis Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Postmenopausal Osteoporosis Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
7.5 India Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Postmenopausal Osteoporosis Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Postmenopausal Osteoporosis Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Postmenopausal Osteoporosis Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Postmenopausal Osteoporosis Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Postmenopausal Osteoporosis Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Postmenopausal Osteoporosis Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Postmenopausal Osteoporosis Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Postmenopausal Osteoporosis Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Postmenopausal Osteoporosis Drugs Price by Type (2015-2020)
11 Global Postmenopausal Osteoporosis Drugs Market Segment by Application
11.1 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2015-2020)
11.2 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Postmenopausal Osteoporosis Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Postmenopausal Osteoporosis Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Postmenopausal Osteoporosis Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025)
12.2.2 Europe Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025)
12.2.4 South America Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025)
12.3 Postmenopausal Osteoporosis Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Postmenopausal Osteoporosis Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Postmenopausal Osteoporosis Drugs Market Share Forecast by Type (2021-2025)
12.4 Postmenopausal Osteoporosis Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Postmenopausal Osteoporosis Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Postmenopausal Osteoporosis Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Postmenopausal Osteoporosis Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Postmenopausal Osteoporosis Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Postmenopausal Osteoporosis Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 8. Eli Lilly Postmenopausal Osteoporosis Drugs Major Business
Table 9. Eli Lilly Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 10. Eli Lilly SWOT Analysis
Table 11. Eli Lilly Postmenopausal Osteoporosis Drugs Product and Services
Table 12. Eli Lilly Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Noven Basic Information, Manufacturing Base and Competitors
Table 14. Noven Postmenopausal Osteoporosis Drugs Major Business
Table 15. Noven Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 16. Noven SWOT Analysis
Table 17. Noven Postmenopausal Osteoporosis Drugs Product and Services
Table 18. Noven Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Novartis Basic Information, Manufacturing Base and Competitors
Table 20. Novartis Postmenopausal Osteoporosis Drugs Major Business
Table 21. Novartis Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 22. Novartis SWOT Analysis
Table 23. Novartis Postmenopausal Osteoporosis Drugs Product and Services
Table 24. Novartis Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Amgen Basic Information, Manufacturing Base and Competitors
Table 26. Amgen Postmenopausal Osteoporosis Drugs Major Business
Table 27. Amgen Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 28. Amgen SWOT Analysis
Table 29. Amgen Postmenopausal Osteoporosis Drugs Product and Services
Table 30. Amgen Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Deltanoid Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Major Business
Table 33. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 34. Deltanoid Pharmaceuticals SWOT Analysis
Table 35. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product and Services
Table 36. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Merck Basic Information, Manufacturing Base and Competitors
Table 38. Merck Postmenopausal Osteoporosis Drugs Major Business
Table 39. Merck Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 40. Merck SWOT Analysis
Table 41. Merck Postmenopausal Osteoporosis Drugs Product and Services
Table 42. Merck Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Osteologix Basic Information, Manufacturing Base and Competitors
Table 44. Osteologix Postmenopausal Osteoporosis Drugs Major Business
Table 45. Osteologix Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 46. Osteologix SWOT Analysis
Table 47. Osteologix Postmenopausal Osteoporosis Drugs Product and Services
Table 48. Osteologix Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Amgen Astellas Biopharm Basic Information, Manufacturing Base and Competitors
Table 50. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Major Business
Table 51. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 52. Amgen Astellas Biopharm SWOT Analysis
Table 53. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product and Services
Table 54. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Allergan Basic Information, Manufacturing Base and Competitors
Table 56. Allergan Postmenopausal Osteoporosis Drugs Major Business
Table 57. Allergan Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 58. Allergan SWOT Analysis
Table 59. Allergan Postmenopausal Osteoporosis Drugs Product and Services
Table 60. Allergan Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 62. Novo Nordisk Postmenopausal Osteoporosis Drugs Major Business
Table 63. Novo Nordisk Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 64. Novo Nordisk SWOT Analysis
Table 65. Novo Nordisk Postmenopausal Osteoporosis Drugs Product and Services
Table 66. Novo Nordisk Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Pfizer Basic Information, Manufacturing Base and Competitors
Table 68. Pfizer Postmenopausal Osteoporosis Drugs Major Business
Table 69. Pfizer Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 70. Pfizer SWOT Analysis
Table 71. Pfizer Postmenopausal Osteoporosis Drugs Product and Services
Table 72. Pfizer Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Tarsa Therapeutics Basic Information, Manufacturing Base and Competitors
Table 74. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Major Business
Table 75. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 76. Tarsa Therapeutics SWOT Analysis
Table 77. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product and Services
Table 78. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. PhytoHealth Basic Information, Manufacturing Base and Competitors
Table 80. PhytoHealth Postmenopausal Osteoporosis Drugs Major Business
Table 81. PhytoHealth Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 82. PhytoHealth SWOT Analysis
Table 83. PhytoHealth Postmenopausal Osteoporosis Drugs Product and Services
Table 84. PhytoHealth Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Radius Health Basic Information, Manufacturing Base and Competitors
Table 86. Radius Health Postmenopausal Osteoporosis Drugs Major Business
Table 87. Radius Health Postmenopausal Osteoporosis Drugs Total Revenue (USD Million) (2018-2019)
Table 88. Radius Health SWOT Analysis
Table 89. Radius Health Postmenopausal Osteoporosis Drugs Product and Services
Table 90. Radius Health Postmenopausal Osteoporosis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Global Postmenopausal Osteoporosis Drugs Sales by Manufacturer (2018-2019) (K Pcs)
Table 92. Global Postmenopausal Osteoporosis Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 93. Global Postmenopausal Osteoporosis Drugs Sales by Regions (2015-2020) (K Pcs)
Table 94. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Regions (2015-2020)
Table 95. Global Postmenopausal Osteoporosis Drugs Revenue by Regions (2015-2020) (USD Million)
Table 96. North America Postmenopausal Osteoporosis Drugs Sales by Countries (2015-2020) (K Pcs)
Table 97. North America Postmenopausal Osteoporosis Drugs Sales Market Share by Countries (2015-2020)
Table 98. North America Postmenopausal Osteoporosis Drugs Revenue by Countries (2015-2020) (USD Million)
Table 99. North America Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries (2015-2020)
Table 100. Europe Postmenopausal Osteoporosis Drugs Sales by Countries (2015-2020) (K Pcs)
Table 101. Europe Postmenopausal Osteoporosis Drugs Sales Market Share by Countries (2015-2020)
Table 102. Europe Postmenopausal Osteoporosis Drugs Revenue by Countries (2015-2020) (USD Million)
Table 103. Asia-Pacific Postmenopausal Osteoporosis Drugs Sales by Regions (2015-2020) (K Pcs)
Table 104. Asia-Pacific Postmenopausal Osteoporosis Drugs Sales Market Share by Regions (2015-2020)
Table 105. Asia-Pacific Postmenopausal Osteoporosis Drugs Revenue by Regions (2015-2020) (USD Million)
Table 106. South America Postmenopausal Osteoporosis Drugs Sales by Countries (2015-2020) (K Pcs)
Table 107. South America Postmenopausal Osteoporosis Drugs Sales Market Share by Countries (2015-2020)
Table 108. South America Postmenopausal Osteoporosis Drugs Revenue by Countries (2015-2020) (USD Million)
Table 109. South America Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries (2015-2020)
Table 110. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales by Countries (2015-2020) (K Pcs)
Table 111. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Market Share by Countries (2015-2020)
Table 112. Middle East & Africa Postmenopausal Osteoporosis Drugs Revenue by Countries (2015-2020) (USD Million)
Table 113. Middle East & Africa Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries (2015-2020)
Table 114. Global Postmenopausal Osteoporosis Drugs Sales by Type (2015-2020) (K Pcs)
Table 115. Global Postmenopausal Osteoporosis Drugs Sales Share by Type (2015-2020)
Table 116. Global Postmenopausal Osteoporosis Drugs Revenue by Type (2015-2020) (USD Million)
Table 117. Global Postmenopausal Osteoporosis Drugs Revenue Share by Type (2015-2020)
Table 118. Global Postmenopausal Osteoporosis Drugs Sales by Application (2015-2020) (K Pcs)
Table 119. Global Postmenopausal Osteoporosis Drugs Sales Share by Application (2015-2020)
Table 120. Global Postmenopausal Osteoporosis Drugs Sales Forecast by Regions (2021-2025) (K Pcs)
Table 121. Global Postmenopausal Osteoporosis Drugs Market Share Forecast by Regions (2021-2025)
Table 122. Global Postmenopausal Osteoporosis Drugs Sales Forecast by Type (2021-2025) (K Pcs)
Table 123. Global Postmenopausal Osteoporosis Drugs Market Share Forecast by Type (2021-2025)
Table 124. Global Postmenopausal Osteoporosis Drugs Sales Forecast by Application (2021-2025)
Table 125. Global Postmenopausal Osteoporosis Drugs Market Share Forecast by Application (2021-2025)
Table 126. Direct Channel Pros & Cons
Table 127. Indirect Channel Pros & Cons
Table 128. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Postmenopausal Osteoporosis Drugs Picture
Figure 2. Global Sales Market Share of Postmenopausal Osteoporosis Drugs by Type in 2019
Figure 3. Antiresorptive Medications Picture
Figure 4. Anabolic Medications Picture
Figure 5. Postmenopausal Osteoporosis Drugs Sales Market Share by Application in 2018
Figure 6. Hospital Picture
Figure 7. Pharmacy Picture
Figure 8. Other Picture
Figure 9. Global Postmenopausal Osteoporosis Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 10. United States Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Canada Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Mexico Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Germany Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 14. France Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. UK Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Russia Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Italy Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. China Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Japan Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Korea Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. India Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Southeast Asia Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Australia Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 24. Brazil Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Egypt Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Saudi Arabia Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. South Africa Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Turkey Postmenopausal Osteoporosis Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Manufacturer in 2019
Figure 30. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Manufacturer in 2019
Figure 31. Top 3 Postmenopausal Osteoporosis Drugs Manufacturer (Revenue) Market Share in 2019
Figure 32. Top 6 Postmenopausal Osteoporosis Drugs Manufacturer (Revenue) Market Share in 2019
Figure 33. Key Manufacturer Market Share Trend
Figure 34. Global Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 35. Global Postmenopausal Osteoporosis Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 36. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Regions (2015-2020)
Figure 37. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Regions in 2018
Figure 38. North America Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
Figure 39. Europe Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
Figure 41. South America Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
Figure 42. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020)
Figure 43. North America Postmenopausal Osteoporosis Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. North America Postmenopausal Osteoporosis Drugs Sales Market Share by Countries (2015-2020)
Figure 45. North America Postmenopausal Osteoporosis Drugs Sales Market Share by Countries in 2018
Figure 46. North America Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 47. North America Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries in 2018
Figure 48. United States Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 49. Canada Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 50. Mexico Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 51. Europe Postmenopausal Osteoporosis Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. Europe Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries (2015-2020)
Figure 53. Europe Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries in 2019
Figure 54. Germany Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. UK Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 56. France Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. Russia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. Italy Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Asia-Pacific Postmenopausal Osteoporosis Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Asia-Pacific Postmenopausal Osteoporosis Drugs Sales Market Share by Regions 2019
Figure 61. Asia-Pacific Postmenopausal Osteoporosis Drugs Revenue Market Share by Regions 2019
Figure 62. China Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Japan Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. Korea Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. India Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. Southeast Asia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. South America Postmenopausal Osteoporosis Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. South America Postmenopausal Osteoporosis Drugs Sales Market Share by Countries in 2019
Figure 69. South America Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries in 2019
Figure 70. Brazil Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. Argentina Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. Middle East and Africa Postmenopausal Osteoporosis Drugs Sales Market Share by Countries in 2019
Figure 74. Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries (2015-2020)
Figure 75. Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue Market Share by Countries in 2019
Figure 76. Saudi Arabia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 77. Egypt Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 78. Turkey Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. South Africa Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. Global Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2025) (K Pcs)
Figure 81. Global Postmenopausal Osteoporosis Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 82. North America Sales Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025) (K Pcs)
Figure 83. Europe Sales Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025) (K Pcs)
Figure 84. Asia-Pacific Sales Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025) (K Pcs)
Figure 85. South America Sales Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025) (K Pcs)
Figure 86. Middle East & Africa Sales Postmenopausal Osteoporosis Drugs Market Forecast (2021-2025) (K Pcs)
Figure 87. Sales Channel: Direct Channel vs Indirect Channel
骨粗しょう症治療薬の世界市場 2020年 Market Overview The Osteoporosis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…- エクセナチド薬の世界市場 2020年 Market Overview The global Exenatide Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Exenatide Drugs market report…
- テデュグルチド薬の世界市場 2020年 Market Overview The global Teduglutide Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Teduglutide Drugs market re…
- ニボルマブ薬の世界市場 2020年 Market Overview The Nivolumab Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade…
- OTC鎮痛薬の世界市場 2020年 Market Overview The global OTC Pain Medications market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The OTC Pain Medications mar…